



COPY OF PAPERS
ORIGINALLY FILED

Patent Application
Attorney Docket No. PC 103087.15

RECEIVED

13/C
15/10/02

UNITED STATES PATENT AND TRADEMARK OFFICE APR 24 2002

IN RE APPLICATION OF: Elizabeth King, et al.

TECH CENTER 1600/2900

APPLICATION NO.: 09/425,622

Examiner: J. Spear
Group Art Unit: 1615

FILING DATE: October 22, 1999

I hereby certify that this correspondence
is being deposited with the United States
Postal Service as First Class Mail in an
envelope addressed to: Assistant Commissioner
for Patents, Washington, D.C. 20231 on

TITLE: Controlled-Release Pharmaceutical
Formulations

Assistant Commissioner for Patents
Washington, D.C. 20231

this 10th day of April 20 02

Sir:

By

Response To Non-Final Office Action

This is in response to the non-Final Office Action dated October 23, 2001 in the above-identified application, the term for response having been extended three (3) months by including the appropriate fee and petition herewith.

In response to the Office Action, please make the following changes to the application:

In the claims:

Please add the following new claims:

31. A sustained-release formulation for oral administration containing a cGMP PDE-5 inhibitor, wherein the cGMP PDE-5 inhibitor is present in a core which is coated with a release rate-controlling membrane, provided that the formulation does not consist essentially of sildenafil, low molecular weight polyethylene oxide, hydroxypropylmethyl cellulose, tabletting excipients, and optionally one or more enteric polymers.

*SB
E1
CJ*